Vivanza Biosciences Limited
BSE: VIVANZA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vivanza Biosciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vivanza Biosciences Limited is an Indian pharmaceutical company focused on the trading and marketing of generic formulations, active pharmaceutical ingredients, and specialized healthcare solutions. The company operates as a small-cap entity, sourcing and distributing medical products to both domestic and international markets.
Business Model
The company generates revenue through the sourcing and distribution of pharmaceutical products, targeting niche therapeutic segments. It leverages a supply chain model to facilitate the trade and marketing of healthcare goods.
Management Commentary
Management is focused on streamlining supply chain operations and enhancing the product portfolio to meet evolving global healthcare demands. The company aims to strengthen its market position by establishing strategic partnerships for international exports.
Growth Outlook
Growth is expected to be driven by the expansion of the company's global footprint and the development of strategic export partnerships. Efforts are being directed towards diversifying the product portfolio to cater to niche therapeutic requirements.
Key Risks
- Regulatory Compliance. The pharmaceutical sector is subject to stringent regulatory oversight, and failure to comply with international quality standards could disrupt operations.
- Supply Chain Volatility. As a trading-focused entity, the company is vulnerable to fluctuations in the availability and cost of active pharmaceutical ingredients.
- Market Competition. The company faces intense competition from larger, well-capitalised pharmaceutical firms that may offer more competitive pricing or broader product ranges.
- Currency and Geopolitical Risk. Expansion into international markets exposes the company to foreign exchange volatility and potential trade barriers in export destinations.
Start your research today
Unlock AI insights, financials, peers and live data on Vivanza Biosciences Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vivanza Biosciences LimitedVIVANZA | ₹7 Cr | — | — | — | 1.0% | — | — | -15.6% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Vivanza Biosciences Limited
BSE: VIVANZA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vivanza Biosciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vivanza Biosciences Limited is an Indian pharmaceutical company focused on the trading and marketing of generic formulations, active pharmaceutical ingredients, and specialized healthcare solutions. The company operates as a small-cap entity, sourcing and distributing medical products to both domestic and international markets.
Business Model
The company generates revenue through the sourcing and distribution of pharmaceutical products, targeting niche therapeutic segments. It leverages a supply chain model to facilitate the trade and marketing of healthcare goods.
Management Commentary
Management is focused on streamlining supply chain operations and enhancing the product portfolio to meet evolving global healthcare demands. The company aims to strengthen its market position by establishing strategic partnerships for international exports.
Growth Outlook
Growth is expected to be driven by the expansion of the company's global footprint and the development of strategic export partnerships. Efforts are being directed towards diversifying the product portfolio to cater to niche therapeutic requirements.
Key Risks
- Regulatory Compliance. The pharmaceutical sector is subject to stringent regulatory oversight, and failure to comply with international quality standards could disrupt operations.
- Supply Chain Volatility. As a trading-focused entity, the company is vulnerable to fluctuations in the availability and cost of active pharmaceutical ingredients.
- Market Competition. The company faces intense competition from larger, well-capitalised pharmaceutical firms that may offer more competitive pricing or broader product ranges.
- Currency and Geopolitical Risk. Expansion into international markets exposes the company to foreign exchange volatility and potential trade barriers in export destinations.
Start your research today
Unlock AI insights, financials, peers and live data on Vivanza Biosciences Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026